Piramal Pharma Solutions Opens New Microbiology Lab in Lexington Kentucky
Published: 08 Oct 2026
Author: Vidyesh Swar
October 2026, Piramal Pharma Solutions opened an innovative microbiology lab at its sterile injectable site in Lexington, Kentucky, to boost quality control and production. The investment improves contamination control and gets the Lexington site ready to meet growing demand for sterile injectables, peptides, bioconjugates, and other complex medicines.
A new Grade A sterility testing isolator is expected to double testing capacity and backing different testing methods. The lab adds more space for tests, new safety cabinets, combined incubators, and a special area for sterility testing. Overall, these improvements should help cut testing times, minimize delays, and speed up batch releases.
Impact on the Pharmaceutical CDMO Sector
The global pharmaceutical CDMO market size is valued at USD 197.40 billion in 2025 and is predicted to increase from USD 211 billion in 2026 to approximately USD 392.67 billion by 2035, expanding at a CAGR of 7.12% from 2026 to 2035.
According to Precedence Research, there is a higher need for cost-efficient equipment and outsourcing of drug. This investment assists Piramal Pharma Solutions in standing out in the pharmaceutical CDMO market by expanding its ability to offer both sterile manufacturing and microbiological testing.
With more testing capacity, the company can improve turnaround times and move products more smoothly from development to production. The move also shows how CDMOs are competing to give clients complete services, faster project delivery, better quality systems, and scalable facilities for complex manufacturing needs.
Impact on the Generic Sterile Injectable Sector
The global generic sterile injectable market size was estimated at USD 56.41 billion in 2026 and it is expected to hit around USD 124.44 billion by 2035, growing at a CAGR of 9.29% during the forecast period 2026 to 2035.
According to Precedence Research, the new laboratory is expected to improve the efficiency of sterile injectable manufacturing by increasing sterility-testing capacity and enhancing contamination control. As demand for complex injectables rises, having a setup like this can enable manufacturers to distinguish themselves.
More rapid microbiology testing will help to reduce the delays between production and batch release, which is important for time-sensitive injectable medicines. Additionally, this investment also shows the industry's move toward advanced isolator systems and the establishment of carefully controlled testing infrastructure.
Impact on the Pharmaceutical Quality Control Sector
The global pharmaceutical quality control market size was calculated at USD 14.43 billion in 2025 and is predicted to increase from USD 16.21 billion in 2026 to approximately USD 43.93 billion by 2035, expanding at a CAGR of 11.78% from 2026 to 2035.
According to Precedence Research, for pharmaceutical companies, R&D labs, and CDMO clients, faster and more reliable quality testing can make manufacturing more predictable. This development shows how important advanced microbiological quality control is becoming in pharmaceutical manufacturing.
A dedicated area for sterility testing helps improve contamination control and product integrity. With more lab space, companies can run tests simultaneously, handle samples better, and work more efficiently. This trend will likely lead to substantial investment in automated, isolated, and GMP-compliant microbiology laboratories.
Expert Opinion
As per an expert point of view, the opening of Piramal Pharma Solutions' new microbiology lab represents an important advance in improving the quality and expanding the growth of sterile injectable manufacturing. The investment is particularly significant as pharmaceutical companies are seeking reliable alliances to work on complex injectables, peptides, and bioconjugates.
Microbiology capabilities could help Piramal compete for more valuable development and manufacturing projects. By increasing its sterility testing capacity and strengthening contamination control, the company will be able to reduce delays and accelerate batch releases. Additionally, this move is part of a larger industry trend toward CDMO facilities that can handle products at all stages.